Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.1 (
protein kinase
)
81,284
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The enzyme termed nowadays
protein kinase CK2
was first described in liver extracts (as a mixture with protein kinase CK1), using casein as artificial substrate, by
Burnett
and Kennedy (1954). In 1960 it was shown that such casein/phosvitin phosphorylating activity was ubiquitous and distinct from phosphorylase kinase, i.e., the only other
protein kinase
known at that time. CK1 and CK2 were distinguished from each other at the end of the sixties, and during the seventies CK2 was purified to homogeneity in several laboratories and thoroughly characterized as far as its subunit structure (alpha 2 beta 2), site specificity, and in vitro responsiveness to various effectors were concerned. The first endogenous substrate for CK2 (eIF-3) was described in 1976, but it was during the eighties that it became clear that CK2 is a pleiotropic
protein kinase
committed with the phosphorylation of a myriad of cellular targets. More than 100 CK2 substrates are known, sharing typical phosphoacceptor sites specified by multiple acidic residues on the C terminal side of Ser/Thr. The definition of the primary structure of CK2 catalytic subunit, in 1987, definitely included CK2 in the big family of eukariotic protein kinases. The growing interest for CK2 is accounted for by its unusual properties, by the increasing number of its substrates, and by several coincidental arguments suggesting that this pleiotropic
protein kinase
plays a fundamental role in cellular regulation. A major and intriguing problem concerning CK2 is its apparent lack of regulation.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:A historical view of protein kinase CK2. 773 12
More than 46 years ago,
Burnett
and Kennedy first described
protein kinase CK2
(formerly known as
casein kinase 2
) in liver extracts. Since then,
protein kinase CK2
has been investigated in many organisms from yeast to man. It is now well established that
protein kinase CK2
is a pleiotropic and ubiquitous serine or threonine kinase, which is highly conserved during evolution. A great number of studies deal with substrates of CK2, but the fact that over 160 substrates exist is more confusing than elucidatory. The holoenzyme is composed of two regulatory beta-subunits and two catalytic alpha- or alpha'-subunits. There is now increasing evidence for individual functions of the subunits that are different from their functions in the holoenzyme. Furthermore, more and more studies describe interacting partners of the kinase that may be decisive in the regulation of this enzyme. A big step forward has been the determination of the crystal structure of the two subunits of
protein kinase CK2
. Now the interactions of the catalytic subunit of CK2 with ATP as well as GTP and the interaction between the regulatory subunits can be explained. However, cellular functions of
protein kinase CK2
still remain unclear. In the present review we will focus our interest on the subcellular localization of
protein kinase CK2
. Protein kinase CK2 is found in many organisms and tissues and nearly every subcellular compartment. There is ample evidence that
protein kinase CK2
has different functions in these compartments and that the subcellular localization of
protein kinase CK2
is tightly regulated. Therefore studying the subcellular localization of
protein kinase CK2
may be a key to its function.
...
PMID:Subcellular localization of protein kinase CK2. A key to its function? 1099 79